JB Capital LLC Acquires New Holdings in Becton, Dickinson and Company $BDX

Key Points

• JB Capital LLC has acquired a new stake of 18,748 shares in Becton, Dickinson and Company, valued at approximately $3.23 million, according to a recent SEC filing.
• Several institutional investors, including Vanguard Group Inc. and T. Rowe Price Investment Management Inc., have increased their holdings in Becton, Dickinson, indicating strong institutional interest.
• Becton, Dickinson reported earnings per share of $3.68 for the last quarter, surpassing analysts’ expectations, and plans to guide for fiscal year 2025 earnings of $14.30 to $14.45.

JB Capital LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 18,748 shares of the medical instruments supplier's stock, valued at approximately $3,229,000.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after purchasing an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the period. JPMorgan Chase & Co. raised its position in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after purchasing an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after purchasing an additional 37,733 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the business's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on BDX shares. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Argus lifted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reiterated a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Weiss Ratings restated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research report on Wednesday. Finally, Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $205.40.

Becton, Dickinson and Company Price Performance

BDX stock opened at $189.06 on Friday. The firm has a 50 day moving average of $189.87 and a 200-day moving average of $186.61. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a market capitalization of $54.19 billion, a P/E ratio of 34.00, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.